MAPK8 and renal carcinoma: In future studies it could be of interest to measure ROS formation and JNK, ERK and P38MAPK phosphorylation in renal cancer cells treated ex vivo with 5F 203 as a putative additional biomarker of renal tumors suitable to be treated with this antitumor agent.